Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: February 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PU-H71

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for PU-H71?

PU-H71 is an investigational drug.

There have been 4 clinical trials for PU-H71. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Thrombocytosis, Lymphoma, and Thrombocythemia, Essential. The leading clinical trial sponsors are Memorial Sloan Kettering Cancer Center, Samus Therapeutics, Inc., and National Cancer Institute (NCI).

There are twenty-seven US patents protecting this investigational drug and one hundred and eighty-four international patents.

Recent Clinical Trials for PU-H71
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking RuxolitinibSamus Therapeutics, Inc.Phase 1
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast CancerSamus Therapeutics, Inc.Phase 1
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast CancerMemorial Sloan Kettering Cancer CenterPhase 1

See all PU-H71 clinical trials

Clinical Trial Summary for PU-H71

Top disease conditions for PU-H71
Top clinical trial sponsors for PU-H71

See all PU-H71 clinical trials

US Patents for PU-H71

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PU-H71   Start Trial Small-molecule Hsp90 inhibitors Sloan-Kettering Institute for Cancer Research (New York, NY)   Start Trial
PU-H71   Start Trial Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy University of Georgia Research Foundation Inc. (Athens, GA)   Start Trial
PU-H71   Start Trial Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta Berg LLC (Nashville, TN)   Start Trial
PU-H71   Start Trial Small-molecule HSP90 inhibitors Memorial Sloan Kettering Cancer Center (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PU-H71

Drugname Country Document Number Estimated Expiration Related US Patent
PU-H71 World Intellectual Property Organization (WIPO) 2006084030 2025-02-01   Start Trial
PU-H71 European Patent Office 3016715 2033-07-01   Start Trial
PU-H71 Japan 2016523926 2033-07-01   Start Trial
PU-H71 World Intellectual Property Organization (WIPO) 2015002996 2033-07-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.